DiaMedica Therapeutics (DMAC) Market Capitalization (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Market Capitalization for 9 consecutive years, with $379.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Market Capitalization rose 126.0% year-over-year to $379.6 million; the trailing twelve-month figure through Jun 2026 stood at $379.6 million (up 126.0% YoY), and the FY2025 full-year result was $427.8 million, up 83.99% from the prior year.
• Market Capitalization grew to $379.6 million in Q2 2026 per DMAC's latest filing, from $364.8 million in the prior quarter.
• Across five years, Market Capitalization topped out at $427.8 million in Q4 2025 and bottomed at $32.8 million in Q3 2022.
• Historically, Market Capitalization has averaged $170.1 million across 5 years, with a median of $122.0 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Market Capitalization slumped 61.54% in 2022, then surged 198.63% in 2023.
• Over 5 years, Market Capitalization stood at $41.8 million in 2022, then surged by 158.02% to $107.8 million in 2023, then soared by 115.68% to $232.5 million in 2024, then soared by 83.99% to $427.8 million in 2025, then retreated by 11.26% to $379.6 million in 2026.
• According to Business Quant data, Market Capitalization over the past three periods registered $379.6 million, $364.8 million, and $427.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.